Literature DB >> 24944842

Glycogen Synthase Kinase 3β in Pancreatic Cancer and its Implications in Chemotherapy and Radiation Therapy.

Qiang Zhang1, Mahaveer S Bhojani1, Edgar Ben-Josef2, Aaron C Spalding3, Rork Kuick4, Yi Sun1, Meredith A Morgan1.   

Abstract

Pancreatic cancer is a highly lethal disease with a poor prognosis characterized by local and systemic disease progression. Both radiation and chemotherapy play important roles in the management of this disease. However, in order to improve standard therapy many molecularly targeted agents are being developed. Glycogen synthase kinase 3β (GSK3β) participates in a multitude of cellular processes and is a newly proposed therapeutic target in pancreatic cancer. This review will discuss both the oncogenic and tumor suppressor functions of GSK3β in pancreatic cancer with an emphasis on the roles of GSK3β in tumor cell survival and sensitivity to radiation and chemotherapy.

Entities:  

Keywords:  GSK3β; Pancreatic cancer; Radiation; c-Met

Year:  2013        PMID： 24944842      PMCID： PMC4059685          DOI： 10.4172/2157-2518.1000147

Source DB:  PubMed          Journal:  J Carcinog Mutagen


  60 in total

Review 1.  Regulation of GSK-3: a cellular multiprocessor.

Authors:  A J Harwood
Journal:  Cell       Date:  2001-06-29       Impact factor: 41.582

Review 2.  The renaissance of GSK3.

Authors:  P Cohen; S Frame
Journal:  Nat Rev Mol Cell Biol       Date:  2001-10       Impact factor: 94.444

Review 3.  GSK-3: tricks of the trade for a multi-tasking kinase.

Authors:  Bradley W Doble; James R Woodgett
Journal:  J Cell Sci       Date:  2003-04-01       Impact factor: 5.285

4.  The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells.

Authors:  James W Welsh; Daruka Mahadevan; Ron Ellsworth; Laurence Cooke; David Bearss; Baldassarre Stea
Journal:  Radiat Oncol       Date:  2009-12-22       Impact factor: 3.481

5.  Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation.

Authors:  K P Hoeflich; J Luo; E A Rubie; M S Tsao; O Jin; J R Woodgett
Journal:  Nature       Date:  2000-07-06       Impact factor: 49.962

6.  A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer.

Authors:  Edgar Ben-Josef; Mathew Schipper; Isaac R Francis; Scott Hadley; Randall Ten-Haken; Theodore Lawrence; Daniel Normolle; Diane M Simeone; Christopher Sonnenday; Ross Abrams; William Leslie; Gazala Khan; Mark M Zalupski
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-04-27       Impact factor: 7.038

7.  Deregulated GSK3{beta} sustains gastrointestinal cancer cells survival by modulating human telomerase reverse transcriptase and telomerase.

Authors:  Wei Mai; Kazuyuki Kawakami; Abbas Shakoori; Satoru Kyo; Katsuyoshi Miyashita; Kenji Yokoi; Mingji Jin; Takeo Shimasaki; Yoshiharu Motoo; Toshinari Minamoto
Journal:  Clin Cancer Res       Date:  2009-11-10       Impact factor: 12.531

8.  Maintenance of constitutive IkappaB kinase activity by glycogen synthase kinase-3alpha/beta in pancreatic cancer.

Authors:  Willie Wilson; Albert S Baldwin
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

9.  CUL4B ubiquitin ligase in mouse development: a model for human X-linked mental retardation syndrome?

Authors:  Yongchao Zhao; Yi Sun
Journal:  Cell Res       Date:  2012-05-15       Impact factor: 25.617

10.  Glycogen synthase kinase-3 inhibition sensitizes pancreatic cancer cells to TRAIL-induced apoptosis.

Authors:  Shadi Mamaghani; Craig D Simpson; Pinjiang M Cao; May Cheung; Sue Chow; Bizhan Bandarchi; Aaron D Schimmer; David W Hedley
Journal:  PLoS One       Date:  2012-07-19       Impact factor: 3.240
View more
  3 in total

1.  Cdc7 overexpression is an independent prognostic marker and a potential therapeutic target in colorectal cancer.

Authors:  Nathaniel Melling; Johanna Muth; Ronald Simon; Carsten Bokemeyer; Luigi Terracciano; Guido Sauter; Jakob Robert Izbicki; Andreas Holger Marx
Journal:  Diagn Pathol       Date:  2015-07-25       Impact factor: 2.644

2.  Anemarrhena asphodeloides Bunge and its constituent timosaponin-AIII induce cell cycle arrest and apoptosis in pancreatic cancer cells.

Authors:  Catherine B MarElia; Arielle E Sharp; Tiffany A Shemwell; Y Clare Zhang; Brant R Burkhardt
Journal:  FEBS Open Bio       Date:  2018-06-11       Impact factor: 2.693

Review 3.  Glycogen Synthase Kinase 3β in Cancer Biology and Treatment.

Authors:  Takahiro Domoto; Masahiro Uehara; Dilireba Bolidong; Toshinari Minamoto
Journal:  Cells       Date:  2020-06-03       Impact factor: 6.600
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.